#Ticagrelor 90 mg Tablets Manufacturers | Explore Tumblr Posts and Blogs

bassyuhi · 2 years

Text

TICAVIC 90 MG TABLET 10

Introduction

Ticavic 90 mg Tablet belongs to the antiplatelet or blood thinners class of drugs. They are prescribed to prevent heart attack and stroke in patients with a high risk of heart disease. It prevents blood clots in persons with acute coronary syndrome. It is a lack of oxygen to the heart who have had stents inserted in their heart arteries. A blood clot stops the heart's blood flow. This artery obstruction causes due to cholesterol, fat, and other substance. This acts by forming a plaque in the heart's arteries (coronary arteries). Chemotherapy can reduce the risk of heart attack by reducing the risk of blood clots.

Ticavic 90 mg Tablet is a blood thinner that prevents blood clots. Platelets are blood cells that cling together and seal blood vessel tears. Yet, in persons at risk of heart attack or stroke, platelets can clump together and form a clot. Heart attacks and strokes are caused due to clots in the heart or brain. Ticavic 90 mg Tablet works by making platelets less sticky.

You should take Ticavic 90 mg Tablet as directed by your doctor. Symptoms include dyspnea, chest tightness, blurred vision, nosebleeds, dizziness, faintness, or lightheadedness. Consult your doctor if symptoms continue. Ticavic 90 mg Tablet may induce bleeding. Don't take it in brain haemorrhage, blood flow issues, or any other risk factor for bleeding.

Alkem Laboratories Ltd is the manufacturer of Ticavic 90 mg Tablet. Ticavic 90 mg Tablet substitutes available in the market are Axcer 90mg Tablet, Ticaspan 90mg Tablet and Brilinta 90mg Tablet. You can find the Ticavic 90 mg Tablet substitutes on different online applications. Ticavic 90 mg Tablet price varies in different countries. Tab Ticavic 90 mg price in India is Rs. 450. But on discount, there may be prize variations. For best offers and discounts give a try to the Truemeds app.

Ticavic 90 mg uses

Acute Coronary Syndrome

It refers to a group of disorders characterised by a rapid decrease in cardiac blood flow. Ticavic is used with aspirin to prevent myocardial infarction, stroke, or death after an acute coronary syndrome.

How does Ticavic 90 mg works?

Ticavic 90 composition has the active ingredient ticagrelor. This is an anti-platelet drug.

Ticavic impacts platelets (also called thrombocytes). These tiny blood cells cluster together to plug tiny holes in blood arteries that have been cut or damaged.

They can clot in damaged blood arteries of the heart and brain. This is risky because:

The clot can block the blood flow, causing a heart attack (myocardial infarction).

The clot might partially obstruct the heart's blood arteries, causing unstable angina.

Ticavic 90 mg Tablet helps prevent deadly blood clots from forming in your vessels. By stopping platelets from adhering together, Ticavic 90 mg help prevent deadly blood clots. It minimises the risk of heart attack, stroke, and Acute Coronary Syndrome in those with heart disease or who just had a stent implanted.

How to take Ticavic 90 mg Tablet?

Always take Ticavic 90 mg Tablet dosage as directed by your doctor. If unsure, consult your doctor. This depends on your condition. Your doctor will recommend you the Ticavic dosage.

Take Ticavic before or after food every day at the same time (for eg, one tablet in the morning and one in the evening).

If you can't take Ticavic tablets, crush them and mix them with water. Drink the mixture immediately, then refill with water, swirl, and drink again. Your doctor will explain how to prepare ticagrelor for NG tube administration.

If you miss a Ticavic tablet, take your next dose as usual. To make up for a missing dose, do not take two pills at once.

Ticagrelor can help avoid significant heart and blood vessel disorders if taken regularly. Even if you feel OK, take ticagrelor. Notify your doctor if you stop taking ticagrelor. Stopping ticagrelor increases your chance of a heart attack or stroke. If you have a stent, stopping ticagrelor too soon increases the risk of a stent blood clot.

Other oral P2Y12 platelet inhibitors should not be used while taking Ticavic.

What are the associated Ticavic 90 mg Tablet side effects?

Every 100th person has these frequent symptoms. If you experience rashes, difficulty breathing, or swelling of your face, lips, tongue. Consult your doctor if any of these symptoms persist:

slow heartbeats;

recurring nosebleeds;

breathing problems, even whether sitting or lying down;

Gout symptoms like joint discomfort and edoema (because ticagrelor can produce high uric acid levels)

bruising, bleeding, or purple or red areas under the skin

change in urine colour;

tarry or bloody stools or

coughing up blood or coffee-ground vomit

headaches

dizziness

feeling sick or indigestion

diarrhoea

constipation

mild rash

When you must not take Ticavic 90 mg Tablet?

Bleeding

Ticavic should be used with caution if you

recently had surgery,

have a history of stomach/intestinal bleeding,

have pre-existing liver problems,

taking certain medicines (e.g. NSAIDs, oral anticoagulants, fibrinolytic)

This may increase your risk of bleeding.

Dyspnoea

Ticavic 90 mg Tablet may cause dyspnoea (shortness of breath). Caution is advised if you have a history of asthma or COPD.

Anomalies of the heart

Ticavic 90 mg Tablet may cause irregular heartbeat. Precaution is advised if you already have heart problems. The ECG and electrolyte levels must be monitored to measure cardiac function.

Surgery

Inform your doctor if you are using Ticavic 90 mg Tablet. Ticavic 90 mg Tablet may increase your risk of bleeding, so stop taking it 5 days before surgery. Depending on your clinical situation, your doctor may recommend a withdrawal time

Creatinine elevation

Creatinine may be increased by Ticavic (0 mg Tablet. After starting this medication, your kidney function should be monitored routinely.

Hyperuricaemia

Ticavic 90 mg Tablet may cause hyperuricemia (high blood uric acid levels). Use with caution if you have hyperuricaemia or gouty arthritis. It is a type of arthritis resulting from the accumulation of uric acid crystals in joint spaces.

Thrombocytopenic purpura

Ticavic may increase your risk of thrombotic thrombocytopenic purpura. It is a rare illness in which blood clots form in small blood vessels all over your body, including the legs

Is it okay to consume alcohol during the use of Ticavic 90 mg Tablet? Does it cause dizziness?

Combining alcohol and drugs increases the risk of reactions. Also reduces or eliminates their effectiveness. Interactions between alcohol and drugs can be harmful or poisonous. Alcohol consumption is not advised.

Most people are unaware that drugs can make them drowsy and unsafe drivers. Avoid driving if you observe any odd changes after taking Ticavic 90mg Tab. Consult your physician.

Is it safe to use Ticavic 90 mg Tablet in pregnant or lactating women?

Ticavic should not be used by women who are or may become pregnant. Women using this drug should use proper contraception to avoid pregnancy. As it is strong medicine, pregnant women should only take it when prescribed by their doctor. Before prescribing this prescription, the doctor will assess the benefits and hazards.

Ticavic 90mg Tab may harm a nursing baby. Use this tablet should only if your doctor says so. A little amount of the medicine may enter into breastmilk and harm the baby. The doctor should decide whether a nursing mother can use this drug.

Ask your doctor before taking it if you are pregnant, nursing, or plan to become pregnant.

What foods or drugs should you avoid while taking Ticavic?

Ticavic interacts with aspirin, warfarin, ibuprofen, citalopram, clarithromycin, rifampicin, carbamazepine, simvastatin, and anti-epileptics.

Ticavic Tablet interacts with grapefruit juice, it can enhance negative effects. Interactions with St John's wort and Ginkgo biloba may increase the risk of bleeding.

Ticavic should not be administered to patients with stomach ulcers, haemophilia, brain haemorrhage, or kidney or liver disorders.

Lifestyle advice when using Ticavic 90 mg Tablet.

Take the medication as prescribed by the doctor. When taking Ticavic, do not take any other OTC drugs, herbal or vitamin supplements.

Keep triglycerides and cholesterol in check.

Eat regularly and eat a nutritious diet of fresh fruits and vegetables.

Alcohol boosts blood pressure and increases heart disease risk.

Obese? Exercise daily to keep your heart healthy.

#blog #medicineblog #usesofmedicine #truemeds

0 notes

myabhijitr · 5 years

Text

Ticagrelor Market - Size, Share, Outlook, and Analysis, 2018-2026

Ticagrelor is used along with aspirin to prevent serious life-threatening problems associated with heart and blood vessels in people suffering with heart attack or severe chest pain. It is also used to prevent development of blood clots with coronary stents in patients having history of heart attack or severe chest pain. The global ticagrelor market is expected to grow at a significant growth rate during the forecast period, owing to high patient pool suffering from heart problems, increasing generic drug development, and improving market access scenarios.

Get PDF Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2515

Increasing burden of heart diseases has direct impact on global morbidity and mortality. For instance, according to American Heart Association and America Stroke Association report 2017 statistics update, cardiovascular disease is listed as the underlying cause of death, accounted for nearly 801,000 deaths in 2017, causing about 1 of every 3 deaths in the U.S. Same source also stated that about 92.1 million American adults were living with some form of cardiovascular disease or the after-effects of stroke in 2017.

Moreover, significant increase in the number of approvals from the U.S. Food and Drug Administration (USFDA) for ticagrelor will aid in the growth of ticagrelor market during the forecast period. For instance, in July 2018, USFDA permitted approval for ticagrelor tablets, manufactured by Alembic Pharmaceuticals, to reduce the rate of cardiovascular deaths and stroke in patients with acute coronary syndrome (ACS), or a history of myocardial infarction (MI).

Report with Discount Available @ https://www.coherentmarketinsights.com/insight/request-discount/2515

Furthermore, instances of product failures will hamper growth of the ticagrelor market during the forecast period. For instance, in October 2016, drug Brilinta containing 90 mg ticagrelor manufactured by AstraZeneca plc failed to demonstrate its benefit over clopidogrel for a new indication in peripheral artery disease (PAD). This led to decreased shares of Brilinta by 1% in October 2016.

North America holds the chief stake in the ticagrelor market, owing to increase in mergers and acquisitions of key players. For instance, in November 2017, PhaseBio Pharmaceuticals, Inc. entered into an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, for PB2452 (formerly MEDI2452), a phase 1-ready reversal agent for ticagrelor. Ticagrelor binds reversibly with the receptors present on platelets.

Europe is also expected to observe significant growth in the global ticagrelor market, owing to increasing approvals for new ticagrelor formulation development in the region. For instance, in May 2017, the European Commission granted marketing authorization for AstraZeneca’s Brilique (ticagrelor) orodispersible tablets (ODT) as a new method of treatment administration. This tablet is effective for patients with difficulty in swallowing and in emergency cases.

Click To Continue Reading On Ticagrelor Market

Key players operating in the ticagrelor market include C.H. Boehringer Sohn AG & Ko. KG, Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Natco Pharma Limited, Anhui Haikang Pharmaceutical Co., Ltd., Avra Laboratories Pvt. Ltd., and Sun Pharmaceutical Industries Ltd.

About Coherent Market Insights:

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link :https://www.coherentmarketinsights.com/phase-xs,

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

#Ticagrelor Market #outlook #analysis

0 notes

kusumsaonerkarblog-blog · 7 years

Text

Ticagrelor Sales Market to Record High Demand by 2017 – 2022

In this report, the global Ticagrelor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Ticagrelor for these regions, from 2012 to 2022 (forecast), covering

United States

China

Europe

Japan

Southeast Asia

India

Ask for sample copy @ https://www.researchtrades.com/request-sample/1215764

Global Ticagrelor market competition by top manufacturers/players, with Ticagrelor sales volume, Price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

Astrazeneca Pharms

Bayer

Johnson & Johnson

Merck

Medtronic Plc.

Spectranetics Corp.

Boston Scientific Corp

Cardiovascular Systems Inc.

Purchase a copy of this report @ https://www.researchtrades.com/checkout/1215764

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

90 mg Tablet

60 mg Tablet

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Ticagrelor for each application, including

Hospital

Pharmacy

Clinic

Key elements for this report:

1 Ticagrelor Market Overview

1.1 Product Overview and Scope of Ticagrelor

1.2 Classification of Ticagrelor by Product Category

1.2.1 Global Ticagrelor Market Size (Sales) Comparison by Type (2012-2022)

1.2.2 Global Ticagrelor Market Size (Sales) Market Share by Type (Product Category) in 2016

1.2.3 90 mg Tablet

1.2.4 60 mg Tablet

1.3 Global Ticagrelor Market by Application/End Users

1.3.1 Global Ticagrelor Sales (Volume) and Market Share Comparison by Application (2012-2022)

1.3.2 Hospital

1.3.3 Pharmacy

1.3.4 Clinic

1.4 Global Ticagrelor Market by Region

1.4.1 Global Ticagrelor Market Size (Value) Comparison by Region (2012-2022)

1.4.2 United States Ticagrelor Status and Prospect (2012-2022)

1.4.3 China Ticagrelor Status and Prospect (2012-2022)

1.4.4 Europe Ticagrelor Status and Prospect (2012-2022)

1.4.5 Japan Ticagrelor Status and Prospect (2012-2022)

1.4.6 Southeast Asia Ticagrelor Status and Prospect (2012-2022)

1.4.7 India Ticagrelor Status and Prospect (2012-2022)

1.5 Global Market Size (Value and Volume) of Ticagrelor (2012-2022)

1.5.1 Global Ticagrelor Sales and Growth Rate (2012-2022)

1.5.2 Global Ticagrelor Revenue and Growth Rate (2012-2022)

2 Global Ticagrelor Competition by Players/Suppliers, Type and Application

2.1 Global Ticagrelor Market Competition by Players/Suppliers

2.1.1 Global Ticagrelor Sales and Market Share of Key Players/Suppliers (2012-2017)

2.1.2 Global Ticagrelor Revenue and Share by Players/Suppliers (2012-2017)

2.2 Global Ticagrelor (Volume and Value) by Type

2.2.1 Global Ticagrelor Sales and Market Share by Type (2012-2017)

2.2.2 Global Ticagrelor Revenue and Market Share by Type (2012-2017)

2.3 Global Ticagrelor (Volume and Value) by Region

2.3.1 Global Ticagrelor Sales and Market Share by Region (2012-2017)

2.3.2 Global Ticagrelor Revenue and Market Share by Region (2012-2017)

2.4 Global Ticagrelor (Volume) by Application

3 United States Ticagrelor (Volume, Value and Sales Price)

3.1 United States Ticagrelor Sales and Value (2012-2017)

3.1.1 United States Ticagrelor Sales and Growth Rate (2012-2017)

3.1.2 United States Ticagrelor Revenue and Growth Rate (2012-2017)

3.1.3 United States Ticagrelor Sales Price Trend (2012-2017)

3.2 United States Ticagrelor Sales Volume and Market Share by Players

3.3 United States Ticagrelor Sales Volume and Market Share by Type

3.4 United States Ticagrelor Sales Volume and Market Share by Application

….

View this report @ https://www.researchtrades.com/report/global-ticagrelor-sales-market-report-2017/1215764

Who we are:

Research Trades has team of experts who works on providing exhaustive analysis pertaining to market research on a global basis. This comprehensive analysis is obtained by a thorough research and study of the ongoing trends and provides predictive data regarding the future estimations, which can be utilized by various organizations for growth purposes.

We distribute customized reports that focus on meeting the client’s specific requirement. Our database consists of a large collection of high-quality reports obtained using a customer-centric approach, thus providing valuable research insights.

Email: [email protected]

Call us: +1 6269994607 / +91 7507349866

Skype ID: researchtradescon

Web: www.researchtrades.com

#researchtrades

0 notes